Maladies inflammatoires de l’intestin chez les personnes âgées
Résumé
L’incidence des maladies inflammatoires de l’intestin (MII) chez les personnes âgées au Canada est passée d’une personne âgée sur 160 en 2018, à une personne âgée sur 88 en 2023, soit 1,14 % de la population âgée. On estime que plus d’un tiers de tous les patients atteints de MII auront plus de 60 ans au cours des 10 prochaines années. La prévalence devrait augmenter en raison de la combinaison des nouveaux diagnostics et de l’avancée en âge des jeunes personnes déjà atteintes d’une MII.
Les personnes âgées atteintes de MII font face à des difficultés uniques que les jeunes personnes atteintes de cette maladie ne connaissent pas, telles que les affections concomitantes, la fragilité, la polypharmacie et un risque accru d’infections et de cancers. Bien que la prise en charge thérapeutique des MII soit similaire chez les personnes âgées et les patients plus jeunes, elle nécessite un examen minutieux de nombreux facteurs différents, ainsi qu’une attention toute particulière lors de l’évaluation des risques et des bienfaits du traitement médical.
Références
Shaffer SR, Kuenzig ME, Windsor JW, Bitton A, Jones JL, Lee K, et al. The 2023 Impact of inflammatory bowel disease in Canada: special populations-IBD in seniors. J Can Assoc Gastroenterol. 2023;6(Suppl 2):S45-s54. doi:10.1093/jcag/gwad013
Axenfeld E, Katz S, Faye AS. Management considerations for the older adult with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2023;19(10):592-599.
Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423-432. doi:10.1136/gutjnl-2012-303864
Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156(5):1345-1353.e1344. doi:10.1053/j.gastro.2019.01.002
Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2020;18(11):2437-2447.e2436. doi:10.1016/j.cgh.2020.02.048
Mak JWY, Lok Tung Ho C, Wong K, Cheng TY, Yip TCF, Leung WK, et al. Epidemiology and natural history of elderly-onset inflammatory bowel disease: results from a territory-wide Hong Kong IBD Registry. J Crohns Colitis. 2021;15(3):401-408. doi:10.1093/ecco-jcc/jjaa181
Everhov AH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Soderling J, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154(3):518-28 e15. doi:10.1053/j.gastro.2017.10.034
Bollegala N, Jackson TD, Nguyen GC. Increased postoperative mortality and complications among elderly patients with inflammatory bowel diseases: an analysis of the national surgical quality improvement program cohort. Clin Gastroenterol Hepatol. 2016;14(9):1274-1281. doi:10.1016/j.cgh.2015.11.012
Schofield JB, Haboubi N. Histopathological mimics of inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(7):994-1009. doi:10.1093/ibd/izz232
Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Crohn’s disease in the elderly: a comparison with young adults. J Clin Gastroenterol. 1998;27(2):129-133. doi:10.1097/00004836-199809000-00005
Chedid VG, Kane SV. Bone health in patients with inflammatory bowel diseases. J Clin Densitom. 2020;23(2):182-189. doi:10.1016/j.jocd.2019.07.009
Bernstein CN, Nugent Z, Shaffer S, Singh H, Marrie RA. Comorbidity before and after a diagnosis of inflammatory bowel disease. Aliment Pharmacol Ther. 2021;54(5):637-651. doi:10.1111/apt.16444
Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2018;24(4):916-923. doi:10.1093/ibd/izx089
Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15(2):182-189. doi:10.1002/ibd.20628
Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16(12):1919-1927.e1913. doi:10.1016/j.cgh.2017.12.052
Kaazan P, Li T, Seow W, Bednarz J, Pipicella JL, Krishnaprasad K, et al. Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of inflammatory bowel disease. JGH Open. 2021;5(9):1063-1070. doi:10.1002/jgh3.12631
Kuenzig ME, Stukel TA, Kaplan GG, Murthy SK, Nguyen GC, Talarico R, et al. Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: a population-based cohort study. J Can Assoc Gastroenterol. 2021;4(2):e16-e30. doi:10.1093/jcag/gwz048
Velissaris D, Pantzaris N, Koniari I, Koutsogiannis N, Karamouzos V, Kotroni I, et al. C-reactive protein and frailty in the elderly: a literature review. J Clin Med Res. 2017;9(6):461-465. doi:10.14740/jocmr2959w
Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians’ guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015;29(7):369-372. doi:10.1155/2015/852723
Huang X, Xiao M, Jiang B, Wang X, Tang X, Xu X, et al. Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis. BMC Gastroenterol. 2022;22(1):534. doi:10.1186/s12876-022-02620-3
Kochar B, Cai W, Cagan A, Ananthakrishnan AN. Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52(2):311-318. doi:10.1111/apt.15821
Qian AS, Nguyen NH, Elia J, Ohno-Machado L, Sandborn WJ, Singh S. Frailty Is independently associated with mortality and readmission in hospitalized patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(10):2054-2063.e2014. doi:10.1016/j.cgh.2020.08.010
Kochar B, Jylhävä J, Söderling J, Ritchie CS, Ludvigsson JF, Khalili H, et al. Prevalence and implications of frailty in older adults with incident inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2022;20(10):2358-2365.e2311. doi:10.1016/j.cgh.2022.01.001
Faye AS, Wen T, Soroush A, Ananthakrishnan AN, Ungaro R, Lawlor G, et al. Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD. Dig Dis Sci. 2021;66(12):4178-4190. doi:10.1007/s10620-020-06746-w
Kochar B, Cai W, Cagan A, Ananthakrishnan AN. Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases. Gastroenterology. 2020;158(8):2104-2111.e2102. doi:10.1053/j.gastro.2020.02.032
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. doi:10.1517/14740338.2013.827660
Wang J, Nakamura TI, Tuskey AG, Behm BW. Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study. Intest Res. 2019;17(4):496-503. doi:10.5217/ir.2019.00050
Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(6):1392-1400. doi:10.1097/mib.0000000000000391
Drittel D, Schreiber-Stainthorp W, Delau O, Gurunathan SV, Chodosh J, Segev DL, et al. Severe polypharmacy increases risk of hospitalization among older adults with inflammatory bowel disease. Am J Gastroenterol. 2025;120(4):844-855. doi:10.14309/ajg.0000000000003036
Asscher VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, Baven-Pronk AMC, van der Marel S, et al. Deficits in geriatric assessment associate with disease activity and burden in older patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022;20(5):e1006-e1021. doi:10.1016/j.cgh.2021.06.015
Mañosa M, Calafat M, de Francisco R, García C, Casanova MJ, Huelín P, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 2018;47(5):605-614. doi:10.1111/apt.14494
Wisniewski A, Kirchgesner J, Seksik P, Landman C, Bourrier A, Nion-Larmurier I, et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterol J. 2020;8(3):303-313. doi:10.1177/2050640619889763
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621-1628.e1621-1625. doi:10.1053/j.gastro.2011.06.050
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617-1625. doi:10.1016/s0140-6736(09)61302-7
Calafat M, Manosa M, Canete F, Ricart E, Iglesias E, Calvo M, et al. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther. 2019;50(7):780-788. doi:10.1111/apt.15458
de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel M, Römkens TEH, et al. Increased discontinuation rates of Anti-TNF therapy in elderly inflammatory bowel disease patients. J Crohns Colitis. 2020;14(7):888-895. doi:10.1093/ecco-jcc/jjaa012
Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, et al. Persistence on anti-tumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: data from the Sicilian Network for inflammatory bowel diseases (SN-IBD). Drugs Aging. 2020;37(5):383-392. doi:10.1007/s40266-020-00744-3
Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials. Clin Gastroenterol Hepatol. 2021;19(5):939-946.e934. doi:10.1016/j.cgh.2020.04.070
Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(9):1736-1743.e1734. doi:10.1016/j.cgh.2018.12.032
Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, et al. Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019;49(9):1188-1194. doi:10.1111/apt.15214
Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Medvedeva E, et al. Efficacy of vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients. Inflamm Bowel Dis. 2022;28(5):734-744. doi:10.1093/ibd/izab163
Cohen NA, Plevris N, Kopylov U, Grinman A, Ungar B, Yanai H, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterol J. 2020;8(9):1076-1085. doi:10.1177/2050640620951400
Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, et al. Safety and efficacy of vedolizumab versus tumor necrosis factor α antagonists in an elderly IBD population: a single institution retrospective experience. Dig Dis Sci. 2022;67(7):3129-3137. doi:10.1007/s10620-021-07129-5
Dar L, Shani U, Dotan A, Ukashi O, Ben-Horin S, Kopylov U, et al. Short-term effectiveness and safety of ustekinumab and vedolizumab in elderly and non-elderly patients with Crohn’s disease: a comparative study. Therap Adv Gastroenterol. 2024;17:17562848241299752. doi:10.1177/17562848241299752
Gebeyehu GG, Fiske J, Liu E, Limdi JK, Broglio G, Selinger C, et al. Ustekinumab and vedolizumab are equally safe and effective in elderly Crohn’s disease patients. Dig Dis Sci. 2023;68(5):1983-1994. doi:10.1007/s10620-022-07770-8
Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56(1):95-109. doi:10.1111/apt.16923
Loftus EV, Jr., Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-1365. doi:10.1111/apt.16060
Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian real-world study of treatment persistence of ustekinumab in Crohn’s disease. Biologics. 2021;15:237-245. doi:10.2147/btt.S310076
Garg R, Aggarwal M, Mohammed A, Achkar JP, Lashner B, Philpott J, et al. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease. Indian J Gastroenterol. 2023;42(5):718-723. doi:10.1007/s12664-023-01391-3
Garg R, Aggarwal M, Butler R, Achkar JP, Lashner B, Philpott J, et al. Real-world effectiveness and safety of ustekinumab in elderly Crohn’s disease patients. Dig Dis Sci. 2022;67(7):3138-3147. doi:10.1007/s10620-021-07117-9
Columbel JF, Danese S, Martin N, Kligys K. Safety profile of risankizumab in Crohn’s disease patients by age: post-hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Gastroenterology. 2023;164(6):S-1091-S-1092. doi:10.1016/S0016-5085(23)03533-3
D’Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940
Lichtenstein GR, Allegretti JR, Loftus EV, Jr., Irving PM, Banerjee R, Charabaty A, et al. Assessment and impact of age on the safety and efficacy of etrasimod in patients with ulcerative colitis: a post hoc analysis of data from the ELEVATE UC clinical program. Inflamm Bowel Dis. 2025. doi:10.1093/ibd/izae308
Regueiro M, Siegmund B, Yarur AJ, Steinwurz F, Gecse KB, Goetsch M, et al. Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical programme. J Crohns Colitis. 2024;18(10):1596-1605. doi:10.1093/ecco-jcc/jjae060
Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, et al. Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program. Inflamm Bowel Dis. 2023;29(1):27-41. doi:10.1093/ibd/izac084
Chowla N, Raseen T, Edward L. S29 Safety of upadacitinib in older patients with ulcerative colitis: a real-world experience. The American College of Gastroenterology.118(12S):S8-S9. doi:10.14309/01.ajg.0000995852.39535.01
Sandborn WJ, Feagan BG, Loftus EV, Jr., Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123-2138.e2128. doi:10.1053/j.gastro.2020.01.047
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian IBD Today 2025
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
